EUVIMEDEUVIMED entdecken
Open Access

What Systemic Hormone Therapy Black Box Removal Means for Breast Cancer Survivors

Versha Pleasant, Kari Ring

JAMA · 03.03.2026 · 335 (9) · 749

DOI: 10.1001/jama.2026.0025 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JAMA, erschienen am 03.03.2026. Verfasst von Versha Pleasant und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics & Gynecology, University of Michigan, Ann Arbor. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 10 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIMHD NIH HHS.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This Viewpoint discusses the benefits and risks of systemic hormone therapy in breast cancer survivors following the US Food and Drug Administration’s removal of black box warnings from menopausal hormone therapy.

Autor:innen und Institutionen

  • Department of Obstetrics & Gynecology, University of Michigan, Ann Arbor.
  • Department of Obstetrics and Gynecology, University of Virginia, Charlottesville.

Förderung

  • NIMHD NIH HHS

Zitieren

APA

Pleasant, V., & Ring, K. (2026). What Systemic Hormone Therapy Black Box Removal Means for Breast Cancer Survivors. JAMA, 335(9), 749. https://doi.org/10.1001/jama.2026.0025

Vancouver

Pleasant V, Ring K. What Systemic Hormone Therapy Black Box Removal Means for Breast Cancer Survivors. JAMA. 2026;335(9):749. doi:10.1001/jama.2026.0025

BibTeX
@article{Pleasant2026,
  author = {Pleasant, Versha and Ring, Kari},
  title = {What Systemic Hormone Therapy Black Box Removal Means for Breast Cancer Survivors},
  journal = {JAMA},
  year = {2026},
  volume = {335},
  number = {9},
  pages = {749},
  doi = {10.1001/jama.2026.0025}
}
Kostenlos starten →